Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

William L. Macias net worth and biography

William Macias Biography and Net Worth

Insider of Immunovant

Presently, William L. Macias is Chief Medical Officer at Immunovant, Inc.

He is also Senior Medical Director at Lilly Research Laboratories.

In his past career he occupied the position of Chief Executive Officer at Focus Biomedical Consulting LLC, Chief Medical Officer of PROMETHERA Biosciences SA and Associate Professor at The Indiana University School of Medicine.

William L. Macias received an undergraduate degree from Marquette University and a doctorate from The Indiana University School of Medicine.

What is William L. Macias' net worth?: The estimated net worth of William L. Macias is at least $9.57 million as of October 16th, 2024. Dr. Macias owns 365,144 shares of Immunovant stock worth more than $9,570,424 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Macias may own. Additionally, Dr. Macias receives a salary of $719,880.00 as Insider at Immunovant. Learn More about William L. Macias' net worth.
How old is William L. Macias?: Dr. Macias is currently 65 years old. There are 6 older executives and no younger executives at Immunovant. Learn More on William L. Macias' age.
What is William L. Macias' salary?: As the Insider of Immunovant, Inc., Dr. Macias earns $719,880.00 per year. There are 2 executives that earn more than Dr. Macias. The highest earning executive at Immunovant is Dr. Peter Salzmann M.B.A., M.D., CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on William L. Macias' salary.
How do I contact William L. Macias?: The corporate mailing address for Dr. Macias and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on William L. Macias' contact information.
Has William L. Macias been buying or selling shares of Immunovant?: During the past quarter, William L. Macias has sold $91,782.52 in Immunovant stock. Most recently, William L. Macias sold 3,188 shares of the business's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $28.79, for a transaction totalling $91,782.52. Following the completion of the sale, the insider now directly owns 365,144 shares of the company's stock, valued at $10,512,495.76. Learn More on William L. Macias' trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, insiders at the sold shares 36 times. They sold a total of 204,388 shares worth more than $6,214,884.80. The most recent insider tranaction occured on October, 23rd when insider Mark S Levine sold 4,361 shares worth more than $128,780.33. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 10/23/2024.

William L. Macias Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/16/2024	Sell	3,188	$28.79	$91,782.52	365,144
1/18/2024	Sell	424	$41.03	$17,396.72	333,173
10/19/2023	Sell	530	$36.80	$19,504.00	336,862
7/19/2023	Sell	426	$24.94	$10,624.44	349,725
4/25/2023	Sell	509	$16.29	$8,291.61	350,151
2/2/2023	Sell	537	$18.24	$9,794.88	262,996
10/21/2022	Sell	341	$9.67	$3,297.47	308,101
7/22/2022	Sell	322	$4.70	$1,513.40	195,626
4/19/2022	Sell	1,392	$4.98	$6,932.16	195,948
1/5/2022	Sell	26,813	$8.28	$222,011.64

William L. Macias Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $26.21

$25.90

$26.47

50 Day Range

MA: $29.18

$25.22

$31.42

2 Week Range

Now: $26.21

$24.61

$45.58

Volume

126,860 shs

Average Volume

1,078,408 shs

Market Capitalization

$3.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

William Macias Biography and Net Worth

What is William L. Macias' net worth?

How old is William L. Macias?

What is William L. Macias' salary?

How do I contact William L. Macias?

Has William L. Macias been buying or selling shares of Immunovant?

Who are Immunovant's active insiders?

Are insiders buying or selling shares of Immunovant?